Histone H3.3B Activators
The term Histone H3.3B Activators refers to compounds that indirectly influence the function of Histone H3.3B through modulation of chromatin remodeling enzymes and histone modification processes. Since Histone H3.3B itself is not directly targeted by specific activators, the focus is on compounds that can affect the enzymes responsible for histone modifications, such as methylation, acetylation, and phosphorylation. HDAC inhibitors like Trichostatin A, SAHA, and MS-275 work by increasing histone acetylation levels, which can lead to a more open chromatin structure and affect the incorporation or function of H3.3B in chromatin. These compounds underline the role of histone acetylation in regulating gene expression and chromatin dynamics.
DNA methyltransferase inhibitors, such as 5-Aza-2'-deoxycytidine and RG108, alter DNA methylation patterns, which can indirectly influence histone modification, including that of H3.3B. Changes in DNA methylation can lead to alterations in chromatin structure and gene expression patterns, thereby impacting H3.3B function. Inhibitors of histone methyltransferases (such as BIX-01294 and EZH2 inhibitors) and lysine demethylase inhibitors play a significant role in modulating histone methylation status. These changes in histone methylation can influence the structure and function of chromatin, thereby affecting the role of H3.3B in gene regulation. Additionally, compounds like JQ1, which inhibits BET bromodomains, and C646, a p300/CBP histone acetyltransferase inhibitor, showcase the complexity of histone regulation and the potential for chemical modulation of these processes, which can indirectly impact Histone H3.3B. Understanding the modulation of Histone H3.3B through these indirect activators is crucial for comprehending the intricate mechanisms of chromatin remodeling and gene expression regulation. Research in this area continues to provide valuable insights into epigenetic regulation and the possibility for interventions in diseases associated with aberrant chromatin dynamics and histone modifications.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An inhibitor of histone deacetylases (HDACs), TSA can influence histone acetylation levels, potentially affecting H3.3B function. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
An inhibitor of DNA methyltransferases, this compound can lead to changes in DNA methylation and indirectly affect histone modification. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Another HDAC inhibitor, SAHA can alter histone acetylation, potentially impacting Histone H3.3B function. | ||||||
Geneticin (G418) Sulfate | 108321-42-2 | sc-29065 sc-29065A sc-29065C sc-29065D sc-29065B | 1 g 5 g 100 g 500 g 25 g | $108.00 $399.00 $1530.00 $6248.00 $469.00 | 193 | |
An inhibitor of histone methyltransferases, Methylstat could indirectly influence H3.3B through changes in histone methylation. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
An inhibitor of G9a histone methyltransferase, which could impact methylation patterns on histones including H3.3B. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
A BET bromodomain inhibitor, JQ1 can affect the reading of histone acetylation marks, potentially influencing H3.3B function. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
A selective p300/CBP histone acetyltransferase inhibitor, possibly influencing acetylation patterns of H3.3B. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
An HDAC inhibitor, MS-275 can alter histone acetylation levels, affecting Histone H3.3B indirectly. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
A DNA methyltransferase inhibitor, RG108 can lead to changes in chromatin structure, potentially impacting H3.3B. | ||||||